carvedilol has been researched along with Renal Insufficiency in 6 studies
Renal Insufficiency: Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Carvedilol is a beta-adrenergic antagonist with vasodilatory properties (alpha1-antagonism), which has been extensively evaluated in the treatment of patients with heart failure." | 8.84 | Carvedilol: use in chronic heart failure. ( Doughty, RN; White, HD, 2007) |
| "This study compared the survival and the risk of heart failure (HF), chronic obstructive pulmonary disease (COPD), diabetes mellitus (DM), hypoglycemia, and renal failure (RF) hospitalizations in geriatric patients exposed to carvedilol or metoprolol." | 7.96 | Metoprolol Versus Carvedilol in Patients With Heart Failure, Chronic Obstructive Pulmonary Disease, Diabetes Mellitus, and Renal Failure. ( Andersen, M; Jensen, MT; Kragholm, K; Rasmussen, DB; Sessa, M; Torp-Pedersen, C, 2020) |
| "Treatment with carvedilol significantly decreased plasma creatinine levels after IRI (up to 168 hr) compared to controls (P < 0." | 5.36 | Carvedilol protects tubular epithelial cells from ischemia-reperfusion injury by inhibiting oxidative stress. ( De Velasco, MA; Hayashi, T; Ishii, T; Nishioka, T; Nose, K; Saitou, Y; Uemura, H, 2010) |
| "Carvedilol is a beta-adrenergic antagonist with vasodilatory properties (alpha1-antagonism), which has been extensively evaluated in the treatment of patients with heart failure." | 4.84 | Carvedilol: use in chronic heart failure. ( Doughty, RN; White, HD, 2007) |
| "This study compared the survival and the risk of heart failure (HF), chronic obstructive pulmonary disease (COPD), diabetes mellitus (DM), hypoglycemia, and renal failure (RF) hospitalizations in geriatric patients exposed to carvedilol or metoprolol." | 3.96 | Metoprolol Versus Carvedilol in Patients With Heart Failure, Chronic Obstructive Pulmonary Disease, Diabetes Mellitus, and Renal Failure. ( Andersen, M; Jensen, MT; Kragholm, K; Rasmussen, DB; Sessa, M; Torp-Pedersen, C, 2020) |
| " Among them, only the once-daily dosing of aminoglycosides has been brought to the clinic and physicians are now increasingly adopting this approach to reduce the toxicity of these agents." | 2.41 | Aminoglycoside nephrotoxicity: do time and frequency of administration matter? ( Beauchamp, D; Labrecque, G, 2001) |
| "Treatment with carvedilol significantly decreased plasma creatinine levels after IRI (up to 168 hr) compared to controls (P < 0." | 1.36 | Carvedilol protects tubular epithelial cells from ischemia-reperfusion injury by inhibiting oxidative stress. ( De Velasco, MA; Hayashi, T; Ishii, T; Nishioka, T; Nose, K; Saitou, Y; Uemura, H, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Sessa, M | 1 |
| Rasmussen, DB | 1 |
| Jensen, MT | 1 |
| Kragholm, K | 1 |
| Torp-Pedersen, C | 1 |
| Andersen, M | 1 |
| Srivastava, S | 1 |
| Kemnic, T | 1 |
| Hildebrandt, KR | 1 |
| Matsuda, N | 1 |
| Hayashi, T | 1 |
| De Velasco, MA | 1 |
| Saitou, Y | 1 |
| Nose, K | 1 |
| Nishioka, T | 1 |
| Ishii, T | 1 |
| Uemura, H | 1 |
| Doughty, RN | 1 |
| White, HD | 1 |
| Beauchamp, D | 1 |
| Labrecque, G | 1 |
2 reviews available for carvedilol and Renal Insufficiency
| Article | Year |
|---|---|
Carvedilol: use in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Diabe | 2007 |
Aminoglycoside nephrotoxicity: do time and frequency of administration matter?
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Carbazoles; Carvedilol; Chronotherapy; Creatinine; | 2001 |
4 other studies available for carvedilol and Renal Insufficiency
| Article | Year |
|---|---|
Metoprolol Versus Carvedilol in Patients With Heart Failure, Chronic Obstructive Pulmonary Disease, Diabetes Mellitus, and Renal Failure.
Topics: Acute Disease; Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Aged | 2020 |
BRASH syndrome.
Topics: Antihypertensive Agents; Atrioventricular Block; Bradycardia; Bumetanide; Carvedilol; Female; Humans | 2020 |
We should not hesitate to use beta-blockers for systolic heart failure with concomitant renal dysfunction.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure, Systolic; Humans; Propanolamines | 2010 |
Carvedilol protects tubular epithelial cells from ischemia-reperfusion injury by inhibiting oxidative stress.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Antihypertensive Agents; Apoptosis; Carbazoles; Carvedilol; Cr | 2010 |